Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar JorgeAura (< 20) Submitted: 2/20/2013 5:34:17 PM : Outperform Start Price: $27.50 DVAX Score: -73.47

For a short-term. 60% yes and 40% no for Hepislav

Featured Broker Partners


Advertisement